Advanced
Trials portfolio
DARWIN 1
Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity
DARWIN1 is an open label, multi-centre single arm phase II trial for eligible patients who relapse whilst taking part in the TRACERx study.
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
DARWIN 2
Deciphering Anti-tumour Response and Resistance With INtratumour Heterogeneity
DARWIN II is a phase II multi-centre non-randomised trial for NSCLC patients to study tumour heterogeneity using genomic analysis. The trial will only be opened in sites participating in the TRACERx s [...]
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
EARL
Electrocautery Ablation for the Prevention of Lung Cancer
EARL is a phase II/III multicentre 2:1 randomised controlled trial to evaluate the effectiveness of electrocautery (EC) in the treatment of high-grade lesions of the lung. All patients consented/regis [...]
Area: Lung cancer
Phase: Phase II/III
Status: In set-up (funded)
IDEAL-CRT
A phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer
IDEAL-CRT is a multicentre phase I/II trial of concurrent chemoradiation with dose-escalated radiotherapy in patients with stage II or stage III Non-Small Cell Lung Cancer.
Area: Lung cancer
Phase: Phase I/II
Status: Closed
Lung Trans
Biomarker Analysis to Predict Response in Lung Cancer
Lung Trans is a non-interventional laboratory study.
Area: Lung cancer
Phase: Laboratory study
Status: In set-up (funded)
MESO-02
A phase I/II study of first line ganetespib with pemetrexed/Cisplatin in patients with malignant pleural mesothelioma
A phase I/II study of first line ganetespib with pemetrexed-platinum in patients with malignant pleural mesothelioma. Phase I follows a 3+3 dose escalation design (cisplatin patients) and an accelerat [...]
Area: Lung cancer
Phase: Phase I/II
Status: Closed
PEACE
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
Posthumous Evaluation of Advanced Cancer Environment Study is a multi-centre prospective observational study
Area: Lung cancer
Phase: Tissue collection
Status: Active (recruiting)
SARON
Stereotactic Ablative Radiotherapy for Oligometastatic Non-small cell lung cancer. A randomised phase III trial
SARON is a randomised, controlled phase III trial of chemotherapy versus chemotherapy + radiotherapy in patients with oligometastatic (1-3 metastases) non-small cell lung cancer (NSCLC) patients. Sub [...]
Area: Lung cancer
Phase: Phase III
Status: Active (recruiting)
Study 15
A multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychlroquine with carboplatin/etoposide therapy in extensive stage small cell lung cancer (SCLC)
Study 15 is a multicentre, randomised trial comparing combination gemcitabine/carboplatin and hydroxychloroquine (HCQ) versus carboplatin/etoposide therapy alone in small cell lung cancer.
Area: Lung cancer
Phase: Phase II
Status: Active (recruiting)
TIMELY
Trial of afatinib in suspected or confirmed mutant EGFR lung cancer patients unfit for chemotherapy
TIMELY was an open label single arm phase II trial using an irreversible second generation EGFR inhibitor, afatinib. Trial afatinib treatment was given to non-small cell lung cancer (NSCLC) patients w [...]
Area: Lung cancer
Phase: Phase II
Status: Closed
TRACERx
TRAcking non small cell lung Cancer Evolution through therapy (Rx)
TRACERx is a prospective observational cohort study of patients with non-small cell lung cancer (NSCLC), in which translational research is the fundamental aspect of the study.
Area: Lung cancer
Phase: Observational trials
Status: Active (recruiting)
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road
London
W1T 4TJ

View map
Email:
ctc.enquiries@ucl.ac.uk
Telephone:
+44 (0)20 7679 9898 (General CTC Enquiries)
Fax:
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2019 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us